logo
logo
Sign in

What makes Qingmu Pharmaceutical an Ideal Afoxolaner Manufacturer and Supplier?

avatar
CNCLathing
What makes Qingmu Pharmaceutical an Ideal Afoxolaner Manufacturer and Supplier?

As one of the trusted afoxolaner API manufacturers and suppliers in China, Qingmu Pharmaceutical offers a comprehensive solution to clients' veterinary API requirements. This article discusses in detail why Qingmu should be your preferred partner for afoxolaner API, highlights their manufacturing and supply chain strengths, and shares real-world client testimonials.

The wide application of afoxolaner API in flea & tick control

Afoxolaner API, with the brand name NexGard, is widely used as an oral formulation to treat and control flea and tick infestations in dogs. After being ingested by dogs, afoxolaner API gets distributed throughout their body. When fleas or ticks bite the dog later on, they ingest the afoxolaner API through the dog's blood. This proves fatal for the parasites as the API acts as an antagonist at the ligand-gated chloride channels in their central nervous system.


By binding to a unique target site within the insect GABA-gated chloride channels, afoxolaner API effectively blocks the pre- and post-synaptic transfer of chloride ions. This leads to uncontrolled neuronal activity in fleas and ticks, resulting in their death. Popular brand names that contain afoxolaner API include NexGard, Frontline, and NexGard Spectra - making it one of the most effective agents globally for controlling flea and tick infestations in dogs.


Why Qingmu Pharmaceutical is a trusted afoxolaner API manufacturer and supplier


As a leading afoxolaner manufacturer with a proven track record, Qingmu has several advantages that make it a reliable supplier:

  • State-of-the-art manufacturing facilities meet strict ICH, US FDA, EU and other compliance standards
  • Rich R&D expertise in process optimization, scale-up and polymorph evaluation
  • In-house quality control lab with advanced analytical instruments like HPLC, GC-MS etc.
  • Approvals from major regulatory bodies like NMPA, FDA, MFDS enhancing product credibility
  • Successful API exports to over 40 countries including the US, Europe and Asia
  • Consistent supply reliability due to robust production planning
  • Competitive pricing for afoxolaner API due to economies of scale

As one of the dominant afoxolaner API suppliers globally, Qingmu has established a strong reputation among leading veterinary drug makers for its reliable and high-quality manufacturing.

What clients say about Qingmu's afoxolaner API & service quality

"We have been sourcing afoxolaner API from Qingmu for our flea & tick products over the past 5 years. Their API quality and consistency has always met our stringent specifications. The pricing is also very competitive. We appreciate their committed service attitude." - Mr. John, Procurement Director, Amvac Chemical Corporation

"As an emerging producer focusing on petcare drugs, Qingmu's expertise in afoxolaner API was invaluable for our R&D projects. Their technical support accelerated our new product development. We highly recommend them as a solution-driven partner." - Dr. Lisa, CSO, PetPharma Ltd.

Concluding thoughts

With its ICH-compliant facilities, strong process R&D capabilities, reliable API supply and competitive pricing, Qingmu Pharmaceutical has emerged as a leading single-source provider for afoxolaner API requirements. Backed by decades of experience, they offer consistent quality and responsiveness valued highly by global customers. If you need an afoxolaner manufacturer or supplier for your veterinary formulations, look no further than Qingmu.

Related reading:


The video above discusses how NexGard (afoxolaner) works to control fleas and ticks in dogs.

Know someone looking for an afoxolaner API manufacturer or supplier? Feel free to share this article.

collect
0
avatar
CNCLathing
guide
Zupyak is the world’s largest content marketing community, with over 400 000 members and 3 million articles. Explore and get your content discovered.
Read more